San Diego, CA based Aethlon Medical has announced that an internal study confirmed the efficacy of its Hemopurifier in removing tumor-secreted exosomes from the blood of patients with metastatic melanoma. The company suggests that because such exosomes can disrupt the body’s immune response to the cancer and can play a role in its spread, their device could become an important tool in the fight against late stage cancers.
From the press release:
Aethlon believes the Hemopurifier® represents the sole therapeutic strategy to directly inhibit or reverse the deleterious effects associated with exosomes secreted by tumors as a survival mechanism for cancer. Tumor-secreted exosomes have been reported to trigger programmed cell death (apoptosis) of immune cells; interrupt T-cell signaling required to mount an immune response; inhibit the production of anti-cancer cytokines, and have implications in the spread of metastasis and allowing for angiogenesis.
In the study, small-scale versions of the Hemopurifier® removed 73% of melanoma derived exosomes from cell culture fluids in one hour and 87% in two hours.
Press release: Aethlon Medical Announces Data Against Metastatic Melanoma
Product page: Hemopurifier
Flashback: Hemopurifier to Treat Infectious Disease